<DOC>
	<DOCNO>NCT02963051</DOCNO>
	<brief_summary>The purpose study determine safety optimal dose intravenous copper chloride disulfiram men metastatic castrate-resistant prostate cancer ( CRPC ) . Eligible men neuroendocrine prostate cancer ( NEPC ) , adenocarcinoma CRPC non-liver/peritoneal metastasis ( lymph node , bone , lung ) adenocarcinoma CRPC liver and/or peritoneal metastasis . Subjects receive three dos intravenous copper chloride take disulfiram oral copper gluconate disease progression ( two year ) . Subjects also undergo PET scan radioactive copper 64 measure level copper tumor . The central hypothesis project ( ) copper chloride disulfiram safe give together ( b ) combination disulfiram copper efficacy mCRPC NEPC .</brief_summary>
	<brief_title>A Phase Ib Study Intravenous Copper Loading With Oral Disulfiram Metastatic , Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Copper</mesh_term>
	<mesh_term>Disulfiram</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Karnofsky performance status ≥ 70 ( Appendix 1 ) 3 . Life expectancy ≥ 12 week determine treat investigator 4 . Adequate laboratory parameter Adequate bone marrow function show : ANC ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L , Hb &gt; 9 g/dL AST/SGOT ALT/SGPT ≤ 2.5 x Institutional Upper Limit Normal ( ULN ) Serum bilirubin ≤ 1.5 x Institutional ULN Serum creatinine ≤ 1.5 x Institutional ULN 24hour clearance ≥ 50 mL/min 5 . Histologically confirm diagnosis prostate cancer . Histologic variant prostate cancer , include neuroendocrine feature small cell carcinoma prostate include . 6 . Radiographic evidence metastatic disease . 7 . Ongoing ADT use LHRH agonist ( e.g . leuprolide , goserelin ) antagonist ( e.g . degarelix ) must continue therapy unless prior bilateral orchiectomy perform . Screening serum testosterone must &lt; 50 ng/dl . 8 . Evidence disease progression ADT evidence one following : 2 consecutive PSA level 50 % great PSA nadir achieve ADT separate least 1 week apart , OR CT MRI base evidence disease progression ( soft tissue , nodal visceral disease progression ) accord PCWG3 criterion RECIST 1.1 criterion , least 1 new bone scan lesion compare immediate prior radiologic study , OR Absolute rise PSA 2.0ng/mL great , minimum 2 consecutive rise PSA level interval ≥ 1 week PSA level 9 . A minimum 2 week elapse antiandrogen therapy prior registration ( i.e . flutamide , nilutamide , bicalutamide ) without evidence antiandrogen withdrawal response . 10 . For subject Groups B C , previous use least one androgen pathway inhibitor ( either abiraterone acetate enzalutamide ) metastatic CRPC 11 . For subject Group A NEPC , previous use least one platinumcontaining chemotherapy regimen . 12 . A minimum 4 week enzalutamide abiraterone applicable . 13 . A minimum 4 week prior chemotherapy , include limited , docetaxel , cabazitaxel , mitoxantrone , carboplatinum , cisplatin , estramustine ; applicable . 14 . A minimum 4 week major surgery prior registration . 15 . Ability swallow , retain , absorb oral medication . 16 . Ability understand willingness sign write informed consent document . 17 . Willingness abstain alcohol alcoholcontaining fluid duration study . Subjects meet follow criterion exclude study : 1 . Symptomatic subject accept treatment approve palliative lifeprolonging therapy , include docetaxel cabazitaxel chemotherapy . ( Note : subject refuse chemotherapy symptomatic immediate need standard systemic therapy may include . ) 2 . History Wilson 's disease copper deficiency . 3 . Uncontrolled hypertension ( systolic BP &gt; 160 mmHg diastolic BP &gt; 95 mmHg ) medical condition could jeopardize assessment toxicity study . 4 . Active symptomatic viral hepatitis chronic liver disease . 5 . Clinically significant heart disease evidence myocardial infarction , arterial thrombotic event past 6 month , severe unstable angina , New York Heart Association ( NYHA ) Class IIIV heart disease cardiac ejection fraction measurement &lt; 50 % baseline . 6 . Atrial Fibrillation , cardiac arrhythmia require therapy . 7 . Corrected QT interval calculate Bazett formula ( QTcB ) &gt; 480 msec . 8 . Other malignancy , except nonmelanoma skin cancer , ≥ 30 % probability death within 24 month . 9 . Administration investigational therapeutic within 30 day Cycle 1 , Day 1 . 10 . Any condition , opinion investigator , would preclude participation trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>metastatic castrate-resistant prostate cancer ( mCRPC )</keyword>
	<keyword>neuroendocrine prostate cancer ( NEPC )</keyword>
	<keyword>adenocarcinoma castrate-resistant prostate cancer ( CRPC )</keyword>
	<keyword>Copper</keyword>
	<keyword>Disulfiram</keyword>
</DOC>